P/E at 31.06 vs Industry's 36.99: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount to Industry P/E

The current P/E ratio of Dr Reddys Laboratories Ltd at 31.06 represents a discount of approximately 16% relative to the sector average of 36.99. This valuation gap suggests the market is pricing in either subdued growth expectations or elevated risks compared to peers. Given the sector’s overall P/E, this discount could reflect concerns about near-term earnings visibility or competitive pressures. However, it also raises the question of whether the stock is undervalued relative to its fundamentals — previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating? The valuation premium or discount often serves as a barometer for investor sentiment and risk appetite within the sector.

Performance Across Timeframes: Mixed Momentum

Examining the stock’s returns reveals a nuanced picture. Over the past year, Dr Reddys Laboratories Ltd has declined by 4.28%, slightly lagging the Sensex’s 3.34% fall. The year-to-date performance is also negative at -5.67%, though it outperforms the Sensex’s steeper -8.65% drop. This suggests some resilience in the stock relative to the broader market during 2026. However, the short-term trend is less favourable. The three-month return of -5.23% contrasts sharply with the Sensex’s 4.34% gain, indicating recent weakness. The one-month return of -2.89% also trails the Sensex’s modest 0.30% rise. This divergence between medium-term underperformance and longer-term relative stability raises questions about the drivers behind the recent sell-off — is this a temporary setback or a sign of deeper challenges?

Moving Average Configuration: Signs of a Partial Recovery

The technical setup of Dr Reddys Laboratories Ltd offers further insight. The stock currently trades above its 5-day and 20-day moving averages, signalling some short-term upward momentum. However, it remains below the 50-day, 100-day, and 200-day moving averages, which typically represent medium to long-term trend indicators. This configuration suggests the stock is experiencing a short-term bounce within a broader downtrend. The recent two-day consecutive fall, with a cumulative decline of 0.73%, tempers this optimism. The opening price of ₹1,196.15 has held steady intraday, but the inability to break above longer-term averages points to resistance levels that must be overcome for a sustained recovery — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings announcements. Out of 22 stocks that declared results, 11 reported positive outcomes, 8 were flat, and 3 posted negative results. This distribution indicates a sector grappling with uneven performance, possibly due to regulatory challenges, pricing pressures, or innovation cycles. Within this context, Dr Reddys Laboratories Ltd’s performance and valuation discount may reflect broader sector headwinds as well as company-specific factors. The stock’s mid-cap market capitalisation of ₹1,00,073 crores places it among the larger players in the sector, yet it faces competition from both established and emerging pharmaceutical companies.

Rating Context: Previously Rated Hold, Now Reassessed

On 13 Jul 2026, the rating for Dr Reddys Laboratories Ltd was updated from Hold to a new assessment. While the current rating is not disclosed, the change signals a reassessment of the company’s fundamentals and market positioning. The previous Mojo Score of 36.0 and a Hold rating reflected cautious optimism tempered by valuation and performance concerns. The updated rating likely incorporates the recent price action, valuation discount, and sector dynamics — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Concluding Analysis: A Complex Picture Emerges

The data on Dr Reddys Laboratories Ltd paints a complex picture. The stock trades at a meaningful discount to its sector’s P/E, suggesting cautious market sentiment. Its performance over the past year and year-to-date shows modest underperformance relative to the Sensex, while the recent three-month decline highlights short-term challenges. The moving average configuration indicates a tentative short-term recovery within a longer-term downtrend. Sector results are mixed, reflecting broader industry uncertainties. The recent rating reassessment from Hold to a new grade underscores the evolving view on the stock’s prospects. Taken together, these factors suggest that while the stock may offer value relative to peers, it also faces headwinds that require close monitoring.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today